There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) , . Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction ; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk  and show no increased risk of adverse events related to the achievement of very low LDL-C levels.
- Coronary Syndromes
- intensive LDL reduction
- improved outcomes
- post acute
Kostner, K., Nicholls, S., Amerena, J., Brown, A., Cooper, M., Hammett, C., O'Brien, R., Kritharides, L., Hare, D. L., Watts, G. F., & Aylward, P. (2016). Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. Heart Lung and Circulation, 25(11), 1051-1054. https://doi.org/10.1016/j.hlc.2016.09.005